Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

People taking GLP-1 drugs can decrease fat mass while minimizing muscle loss with a few key strategies that include proper ...

US stocks trimmed early session gains on Monday morning, as investors focused on tech's significant — if temporary — reprieve ...

US stocks edged higher Monday morning, as investors focused on tech's significant — if temporary — reprieve from President ...

Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its ...

Over the last three years, diversification has fallen out of fashion. When investors can make 20% or higher returns in ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...